Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease

Overview

The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.

Full Title of Study: “Study of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2015

Interventions

  • Other: 31-Phosphorus RMN Spectroscopy

Arms, Groups and Cohorts

  • Other: Patients
    • 31-Phosphorus RMN Spectroscopy
  • Other: Volunteers
    • 31-Phosphorus RMN Spectroscopy

Clinical Trial Outcome Measures

Primary Measures

  • Ratio of Inorganic Phosphate (Pi) over phosphocreatine (PCr): Pi/PCr
    • Time Frame: 2 years
    • 31P-MRS allows quantification of high-energy phosphate metabolites such as phosphocreatine and inorganic phosphate

Secondary Measures

  • Correlation between primary outcome measure and clinical parameters
    • Time Frame: 2 years
    • Correlating a brain energy deficit with clinical parameters in Huntington patients such as the Unified Huntington’s disease rating scale (UHDRS) and total functional capacity score (TFC).
  • Study of longitudinal changes in Pi/PCr ratio over time.
    • Time Frame: 2 years
    • Patients will be retested after one month.

Participating in This Clinical Trial

Inclusion Criteria

  • UHDRS < 50 – Age > 18 years – Ability to undergo MR scanning – Covered by french social security Exclusion Criteria:

  • Evidence of psychiatric disorder – Attendant neurological disorder – Contraindications to MRI (claustrophobia, metallic or material implants) – Severe head injury – Unable to understand the protocol – Pregnancy – Failure to give informed consent – Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent) – Unwillingness to be informed in case of abnormal MRI

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Institut National de la Santé Et de la Recherche Médicale, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Fanny Mochel, MD, PhD, Principal Investigator, INSERM UMR S975 Institut du Cerveau et de la Moelle, AP-HP Département de Génétique, Université Pierre et Marie Curie, Paris France

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.